Intranuclear Signaling Cascades Triggered by Nuclear GPCRs by Cattaneo, Fabio et al.
Intranuclear Signaling Cascades Triggered by Nuclear GPCRs
Fabio Cattaneo1, Melania Parisi1, Tiziana Fioretti2, Gabriella Esposito1,2* and Rosario Ammendola1
1Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples Federico II, Via S. Pansini 5, Naples, Italy
2IRCCS SDN, Via E. Gianturco 113, Naples 80143 Italy
*Corresponding authors: Rosario Ammendola, Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples Federico II, Via S.
Pansini 5, Naples, Italy, Tel: +39 081 7463145; Fax: +39 081 7464359; E-mail: rosario.ammendola@unina.it
Gabriella Esposito , Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples Federico II, Via S. Pansini 5, Naples 80131,
Italy. IRCCS SDN Via E. Gianturco 112n Naples 80143, Italy. Tel: +39 081 7463147; Fax +39 081 7464359; E-mail: gabriella.esposito@unina.it
Received date: Oct 5, 2016; Accepted date: Nov 3, 2016; Published date: Nov 21, 2016
Copyright: © 2016 Cattaneo F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
G protein-couped receptors (GPCRs) play a key role on cellular membranes, where they respond to a broad
array of extracellular signals such as lipids, peptides, proteins and sensory agents. Intracellular biological responses
triggered by these receptors include hormone secretion, muscle contraction, cellular metabolism a tyrosine kinase
receptors transactivation. Recent results indicate that GPCRs localize to and signal also at nuclear level, thus
regulating distinct signaling pathways which can also result from the integration of extracellular and intracellular
stimuli. Nuclear GPCRs play a central role in many cellular processes, including regulation of gene transcription,
cellular proliferation, neovascularization and RNA synthesis. On nuclear membranes and in nucleoplasm are present
all the downstream signal transduction components of GPCRs, including G proteins, adenylyl cyclase, and second
messengers such as Ca++, ERKs, p38MAPK and other protein kinases. Nuclear GPCRs may be constitutively active
or may be activated by ligands internalized from the extracellular space or synthesized within the cell. The
translocation of membrane receptors to the nucleus could be attributed to the presence of a Nuclear Localization
Signal, which is present in the eighth helix or in the third intracellular loop of a limited number of GPCRs. However,
several sequence motifs that do not resemble classical Nuclear Localization Signals can promote import of GPCRs.
In this review we discuss the most recent results on nuclear localization and signaling of several GPCRS.
Keywords: G protein-coupled receptors; Nuclear localization; Signal
transduction
Introduction
G protein-coupled receptors comprise a large family of heptahelical
transmembrane proteins involved in cellular signaling [1]. They
represent the largest class of gene products targeted by therapeutic
agents and recognized by extracellular stimulants of diverse nature [2].
GPCRs are viewed as cell surface functional entities and have been
classified into seven families, based on phylogenic analysis of the seven
transmembrane domain [3,4]. In conventional GPCR signaling,
stimulation with a specific agonist triggers the dissociation of
heterotrimeric G proteins. α and βγ subunits can stimulate
downstream effector molecules associated with several cellular
signaling pathways, thereby altering the generation of second
messengers (e.g. cAMP, cGMP, inositol triphosphate, diacylglicerol,
Calcium, nitric oxide). These signals are negatively regulated by
intrinsic GTPase activity of Gα subunits, G protein-coupled receptor
kinases (GRKs), β-arrestins, metabolism of second messengers,
regulators of G proteins (RGS) signaling or internalization and down-
regulation of the receptor [5].
Several independent studies have revealed that endocytosed GPCRs
may regulate distinct signaling pathways, suggesting that the GPCR-
mediated biological responses may also result from the integration of
extracellular and intracellular signaling events [6-9]. Intracellular
GPCRs may be constitutively active, or may be activated by agonists
internalized from the extracellular space or synthesized within the cell.
Furthermore, a number of GPCRs also localize to and signal at the
nuclear membrane or within the nucleus in several cell types [4].
GPCRs may be inserted into nuclear membranes where they compose
distinctive signaling units which respond to specific intracellular
ligands by transducing nuclear transcriptional signals. They can
regulate signaling cascades distinct from those activated by the same
receptor on plasma membrane. Nuclear GPCRs may be constitutively
active or activated by endogenous non-secreted ligands, thus
regulating several physiological processes, such as cell proliferation,
DNA synthesis, transcription and inflammatory responses [10-13]. A
large number of downstream signal transduction components,
normally associated with GPCRs at cell surface, are present in the
nucleus and/or on the nuclear membranes including G proteins,
adenylyl cyclases, phospholipases A2, Cβ and D, ion channels, β-
arrestins and GRKs [14]. Furthermore, several signaling pathway
components molecules, such as ERKs, p38MAPK, PKB, PKA and PKC
are activated upon binding of cognate ligands to nuclear GPCRs
[15-18]. The nuclear import of proteins into the nucleus involves the
recognition of a nuclear localization signal (NLS), embedded in the
protein, by importins. The most frequently encountered NLS consists
of short stretches of mono- or bi-partite basic aminoacids residues
(usually lysine-arginine or glycine-arginine repeats), even though
several heterogenous sequences that do not resemble to classical basic
NLS can promote nuclear import of several proteins [19]. A NLS motif
has been identified in the eight helix or in the third intracellular loop
of several GPCRs [20]. Here in we discuss the most recent results on
nuclear localization and signaling of GPCRs.
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Adrenergic Receptors
In mammalian cardiomyocytes three β-adrenergic receptors (β-
ARs) are expressed and their nuclear localization is subtype specific.
β1-AR and β3-AR, but not β2-AR, are expressed onto nuclear
membrane and both receptors are differentially coupled to signaling
pathways in isolated heart nuclei [21]. β1-AR stimulates Gs protein
and activates adenylyl ciclase (AC), whereas β3-AR stimulates Gi and
modulates transcriptional initiation in a PTX-sensitive manner [21]. In
isolated cardiac nuclei, isoproterenol, a β3-AR selective agonist,
stimulates PTX-sensitive de novo RNA synthesis and other signaling
pathways in addition to Gi [22]. Stimulation of nuclear β-AR also
induces up-regulation of 18S rRNA and a decrease in NF-κB mRNA, as
well as mRNAs for genes involved in the NF-κB signaling pathway [5].
The transcriptional events mediated by nuclear β-AR are sensitive to
p38MAPK, ERKs, Akt, and JNK inhibitors, suggesting that these
pathways are involved in nuclear signaling [21,23]. The principal
endogenous agonists for β-ARs are nor-adrenaline and adrenaline,
which are not produced or secreted by β-AR-expressing cells in the
heart. The interaction of nuclear β-ARs with the cognate ligands
requires the transport of agonists to the nucleus. In neonatal and adult
cardiomyocytes, nor-adrenaline is rapidly internalized and in neonatal
rat ventricular cardiomyocites norepinehrine is transported to the
nucleus [24]. Nuclear β-ARs can also regulate nitric oxide (NO)
production, as demonstrated by the observation that isoproterenol
increases NO production and that BRL 37344, a β3AR-selective
agonist, increases NO synthesis in nuclei isolated from adult rat heart
[25]. The orphan nuclear receptor Nur77 plays critical roles in
cardiovascular diseases, and its expression is markedly induced in the
heart after β-AR activation. In a time- and dose-dependent manner,
isoproterenol and the overexpression of Nur77 increases the expression
of this receptor in the nuclei of cardiomyocytes. Nur77 functionally
interacts with NFATc3, a transcriptional factor involved in multiple
cardiac hypertrophic signaling in the nuclei of cardiomyocytes, and
GATA4 and inhibits their transcriptional activities, which are critical
for the development of cardiac hypertrophy (Table 1) [26].
The three α1-adrenergic receptors (α1-ARs) subtypes (A, B, and D)
are expressed in the heart, but cardiac myocites only express the α1A
and the α1B receptor. In these cells, activation of endogenous nuclear
α1-ARs induces Gαq, and PLCβ1 activation, which localize to the
nucleus, as well as the accumulation of phosphorylated ERKs [27]. The
α1A and β1B subtypes co-localize at the nucleus with the formation of
receptor oligomers that affect receptor signaling [27], but no direct
demonstration has been provided for interaction between β1-AR and
β3-AR in the nucleus (Table 1) [21]. In the two α1-AR subtypes has
been identified a bipartite NLS in α1A and a glycine-arginine repeat/
arginine rich NLS in the α1B, in the carboxyl tail region of the
respective receptors (Table 2) [28].
Endothelin Receptors
Endothelins act through two specific GPCR subtypes, ETAR and
ETBR. ETAR is primarily expressed on surface membranes and
transverse-tubules and to a lesser extent on nuclei isolated from the
heart, while ETBR localizes primarily to the nuclei [29]. Nuclear
endothelin receptors are capable of specific ligand binding and their
stimulation induces a transient increase in nuclear cisternal Ca++
content, as well as the activation of endogenous nuclear protein kinases
[29]. Furthermore, in human endocardial endothelial cells, in human
aortic vascular smooth muscle cells and in adult rat heart, endothelin-1
(ET-1) induces an increase in nuclear Reactive Oxygen Species [30]
and NO (Table 1) [25]. In cardiac nuclear membranes, the endothelin
receptor is ETBR and the absence of N-glycosylation indicates that this
receptor did not originate at the cell surface but traffics directly to the
nuclear membrane after biosynthesis [31]. ETBR associated with the
nuclear membranes regulates nuclear Ca++ signaling through an IP3-
dependent pathway and exogenous endothelins are not ligands for for
this receptor on nuclear membranes [31]. In fetal human left
ventricular endocardial endothelial cells (EECLs), both plasma
membrane ETAR and ETBR mediate ET-1-induced increase of
intracellular calcium; this effect is mediated only by ETAR in right
EECs (EECRs). On nuclear membrane of EECRs both ETAR and
ETBR mediate the effect of cytosolic ET-1 on nuclear Ca++ increase. In
contrast, in EECLs only nuclear membrane ETBR activation mediates
the effect of cytosolic ET-1 [32]. A NLS motif has been identified in the
eighth helix of ETAR and ETBR (Table 2) [20].
Vasoactive Intestinal Peptide Receptors
Vasoactive intestinal peptide (VIP) and its receptors (VPACs) are
involved in proliferation, survival, and differentiation in several cell
types. In human breast tissue samples VPAC1 is localized in cell
nuclear fraction, whereas VPAC2 presents an extranuclear localization
and its protein expression is lower than that of VPAC1 [33]. Both
receptors are overexpressed in breast cancer and in estrogen-
dependent and -independent human breast cancer cell lines the
nuclear localization of VPAC1 is markedly enhanced. In these cells
VPAC1 receptor is functional in nuclear membrane as demonstrated
by cAMP production upon VIP stimulation. VIP seems to be involved
in the regulation of VPAC1-receptor traffic from the plasma
membrane to the nucleus [33]. VPACs are also involved in the
regulation of glioma cell proliferation and migration (Table 1). In three
human glioblastoma (GBM) cell lines, a strong nuclear staining for the
VPAC1 receptor has been detected, which is correlated to glioma
grades and to glioma progression [34].
GPR158
GPR158 belongs to the human GPCR family C, which contains 22
receptor subtypes [35], and is phylogenetically related to the GABA
receptors. It is expressed in a variety of tissues, but it is expressed at
highest levels in the brain. In cultured trabecular meshwork cells,
glucocorticoid (GC) treatment and the transient overexpression of
GPR158 stimulates levels of GPR158 mRNA and protein through
transcriptional mechanisms [36]. Both endogenous and overexpressed
GPR158 show an unusual subcellular localization pattern, being found
almost entirely in the nucleus. The transient overexpression of GPR158
stimulates cell proliferation, up-regulates levels of the cell cycle
regulator cyclin D1 and increases the levels of tight junction proteins
ZO-1 (Table 1) [36]. Nuclear localization of endogenous and
overexpressed GPR158 is prevented by inhibitors of clathrin-mediated
endocytosis. This suggests that GPR158 traffics to the plasma
membrane, where it rapidly undergoes endocytosis and translocation
to the nucleus. A bipartite NLS has been identified in the eighth helix,
at the proximal end of the C-terminal cytoplasmic tail of the receptor
(Table 2) [36].
Chemokine Receptor Cysteine 4
Chemokine Receptor Cysteine 4 (CXCR4) is associated with the
nucleus of malignant prostate cancer tissues. Likewise, expression of
CXCR4 is detected in nuclear fractions among several prostate cancer
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cell lines, compared to normal prostate epithelial cells [37]. A putative
NLS (RPRK) between aminoacids 146-149 within CXCR4 that
contributes to nuclear localization has been identified (Table 2).
Nuclear CXCR4 interacts with Transportin β1 promoting CXCR4
nuclear translocation and its participation in nuclear G-protein
signaling, as demonstrated by Ca++ mobilization and Gαi
immunoprecipitation (Table 1) [37]. Emerging evidence demonstrates
that CXCR4 translocates into the nucleus to facilitate cell migration
and, therefore, determine the prognosis of several types of
malignancies. However, the biological mechanism of nuclear location
of CXCR4 remains unclear. Non-muscle myosin heavy chain-IIA
(NMMHC-IIA) has been identified as a nuclear CXCR4-interacting
protein and pharmaceutical inhibition of NMMHC-IIA dampenes the
nuclear translocation of CXCR4, as well as the metastatic capacity of
renal carcinoma cells [38].
Nuclear
GPCR Signalling Ref.
-ARs
Gs stimulation, AC activation, Gi stimulation,
RNA synthesis, Up-regulation 18S RNA,
Decrease NFkB mRNA, p38MAPK, ERKs, Akt,
JNK activation, NO production, nuclear Nur77
expression [21,23,25,26]
-Ars
Gaq stimulation, PLCb1 activation, ERKs
activation,Formation of receptor oligomers [27]
Endothelin
receptors
Increase in [Ca++], Activation protein kinases,
Increase Reactive Oxygen Species, Increase
NO [25,29,30]
VPAC1
cAMP production, Cell proliferation and
migration [33,34]
GPR158
Cell proliferation, Up-regulation cyclin D1,
Increases tight junction proteins ZO-1 [36]
CXCR4 [Ca++] mobilization, Gai stimulation, [37]
B2R
[Ca++] mobilization, Akt activation,Acetylation
histone H3, iNOS gene induction [39]
OTR
Osteoblast differentiation genes, ERKs
phosphorylation [44]
UT
RNA synthesis, IP3 activation, [Ca++]
mobilization, CREB and DREAM activation [45,47]
AT1R/AT2R
p62 phosphorylation, RNA synthesis, NFkB
expression, [Ca++] mobilization [48,49]
F2rl1
Recruitment of Sp1, Vegfa expression,
neovascularization [50]
PAF receptor
Transcriptional regulation of cyclooxygenase-2
and iNOS, decrease in cAMP, [Ca++]
mobilization, ERKs phosphorylation, NFkB
activation [52,53,54]
LPA1R
[Ca++] mobilization, iNOS and
cyclooxygenase-2 expression, proteins
phosphorylation [55]
EP receptors
[Ca++] mobilization, gene transcription, iNOS
expression, ERKs and Akt phosphorylation [58,59,60]
GnRHRs acetylation and phosphorylation of histone H3 [62]
Nuclear
Opioid
Receptors
increased opioid peptide gene transcription,PKC
activation [64]
CysLT1
Proliferative ERKs signaling, [Ca++]
mobilization,up-regulation PAI-2 mRNA, [65,66]
mGlu5 [Ca++] mobilization, CREB phosphorylation [72,73]
FPR2
Gii stimulation, p42MAPK phosphorylation, c-Jun
and c-Myc phosphorylation [74]
Table 1: Signalling pathways triggered by nuclear GPCRs β-ARs: β-
Adrenergic receptors; α-ARs: α-Adrenergic receptors; VPAC1:
Vasoactive intestinal peptide receptor 1; CXCR4: Chmokine Receptor
Cysteine 4; B2R: Bradikinin B2 receptor; OTR: Oxitocyn receptor; UT:
Urotensin II receptor; AT1R/AT2R: Angiotensin II receptors; F2rl1:
Coagulation Factor II Receptor-like 1; PAF receptor: Platelet-activating
factor Receptor; LPA1R: Lysophosphatidic acid receptor-1; EP
receptors: Prostaglandin E receptors; GnRHRs: Gonadotropin-
Releasing Hormone Receptors; CysLT1: Cysteinyl Leukotriene 1
receptor; mGlu5: Metabotropic Glutamate receptor; FPR2: Formyl-
peptide Receptor 2; AC: Adenylyl Cyclase; NO: Nitric Oxide; PLCβ1:
phospholipase Cβ1; IP3: Inositol triphosphate; PKC: Protein Kinase C.
Bradykinin B2 Receptors
The mechanism of action of Bradykinin (BK) is primarily mediated
by specific cell surface membrane B2 receptors (B2Rs). Some evidence
has suggested, however, the existence of an intracellular/nuclear B2R
population. Whether these receptors are functional and contribute to
BK signaling remains to be determined. Nevertheless, highly purified
nuclei from isolated rat hepatocytes contain a specific B2R that bind
BK, inducing concentration-dependent transitory mobilization of
nucleoplasmic calcium [39]. This response is prevented by B2R but not
B1R antagonists. Furthermore, in isolated nuclei BK triggers Akt
activation, acetylation of histone H3, which binds to promoter region
of iNOS gene and ensuing pro-inflammatory iNOS gene induction
[39]. This suggests that nuclear-localized B2R responsive to BK
binding functions is a transcriptional regulator of specific genes (Table
1).
The transfer of B2R membrane to the nucleus can be attributed to
the presence of a NLS motif (310-KRFRK-314), positioned just
downstream of the seventh trans membrane domain within the eighth
helix (Table 2) [40]. Mutation of the NLS sequence does not change
nuclear distribution of B2R [40]. Nuclear B2R forms heterodimers with
nuclear membrane protein lamin C and the sequence 303-320 in B2R
has been identified as lamin C protein binding motif [41]. Interestingly,
BK addition does not reduce the binding to lamin C or changes the
distribution of B2R. The formation of this heterodimer seems to be
essential to nuclear localization of B2R and plays an important role in
cell signaling and function [41]. Agonist-independent nuclear
localization of B2R has been demonstrated [20]. Nuclear B2R has been
also detected in extravillous trophoblasts, where its expression is
greater in the normal than in the preeclamptic placentas [42].
Oxytocin receptor
Oxytocin receptor (OTR) is a membrane GPCR known to mediate
oxytocin (OT) effects, in both normal and neoplastic cells. However,
human osteosarcoma (U2OS, MG63, OS15 and SaOS2), breast cancer
(MCF7), and primary human fibroblastic cells (HFF) all exhibit OTR
not only on the cell membrane, but also in the various nuclear
compartments including the nucleolus [43]. OT induces
internalization of OTR. The resulting vesicles accumulate in the
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proximity of the nucleus and some of the perinuclear OTR enters the
nucleus. OTR is first visible in the nucleoli and subsequently disperses
within the nucleus, while other OTR diffuses throughout the
nucleoplasm. Some cells require a ligand for transfer of OTR in nuclei.
A constitutive internalization of OTR is observed only in osteosarcoma
cells, while the nuclear localization in all other cells types is dependent
on ligand binding. The amount of OTR within and in the proximity of
the nucleus increases upon the treatment with OT in both constitutive
and ligand-dependent type of cells [43]. In osteoblasts OT-dependent
nuclear OTR translocation plays a key role in osteoblast maturation
[44]. The passage of OTR into the nucleus is facilitated by successive
interactions with β-arrestins, the small GTPase Rab5, importin-β, and
transportin-1. siRNA-mediated knockdown of β-arrestins or
transportin-1 inhibits OT-induced expression of the osteoblast
differentiation genes without affecting ERKs phosphorylation (Table 1)
[44]. Putative simple and bipartite NLSs are located within the
cytoplasmic segments of OTR and include the following three clusters
of positively charged amino acids: RTTRQKHSR (1st intracellular
loop, aa 65-73), RSLRRRTDR (2nd intracellular loop, aa 146-154) and
KGRR-7aa-KK (C-terminus, aa 353-365) (Table 2) [43].
Urotensin II receptor
In rat and monkey heart and central nervous system, Urotensin-II
receptor (UT) is expressed at nuclear/perinuclear level. Both
endogenous ligands of UT, urotensin-II and urotensin-II-related
peptide (U-II and URP) are able to cross the plasma membrane in a
receptor-independent manner and to activate the nuclear receptor. The
activation by U-II or URP results in different modulatory effects on
transcription [45]. Interestingly, the presence of different post-
translational modifications between membrane and nuclear UT in
brain extracts has been observed, and membrane and nuclear UT are
differentially modulated in regard to subcellular localization [46]. U-II
and URP induce de novo RNA synthesis which is prevented by an UT
antagonist. Nuclear UT could induce transcription through a pathway
involving the production of IP3 that would trigger IP3 receptor at the
inner nuclear envelope, releasing calcium in the nucleoplasm. This
latter event is crucial for the activation of transcription factors CREB
and DREAM (Table 1) [47]. A NLS (Lys-Arg-Ala-Arg-Arg) is present
in the third intracellular loop of human and monkey UT isoforms,
while a Lys-Gln-Thr-Arg-Arg segment is observed in rat and mouse
UT (Table 2) [47]. However, it is important to note that many NLS
signals are still unknown and that the presence of an obvious NLS
motif may mask the existence of still uncharacterized NLS sequences.
Nuclear
GPCR NLS Ref.
α1-AR
(subtype A) Bipartite NLS in the carboxyl tail region [28]
α1-AR
(subtype B) GR repeat/R rich in the carboxyl tail region [28]
ETAR KKFK in the eighth helix [20]
ETBR KRFK in the eighth helix [20]
GPR158 Bipartite NLS in the eighth helix [36]
CXCR4 RPRK (amino acids 146-149) [37]
   
B2R
KRFRK (amino acids 310-314) in the eighth
helix [20,40]
OTR
Three clusters of positively charged amino
acids: RTTRQKHSR (1st intracellular loop, aa
65-73), RSLRRRTDR (2nd intracellular loop, aa
146-154) KGRR-7aa-KK (C-terminus, aa
353-365). [43]
UT
KRARR (human/monkey); KQTRR (rat/
mouse)in the third intracellular loop [47]
AT1R KKFKR in the eighth helix [20,48]
Apelin
receptor RKRRR in the third intracellular loop [20]
PAF
receptor
RSSRKCSRATTDTVTEVVVP (amino acids
311-320) in the carboxyl tail region [54]
GnRHs
KKEKGKK (amino acids 66-72) in the first
intracellular loop [62]
CysLT1
Bipartite NLS: RKHSLSSVTYVPRKK (amino
acids 310-324) in carboxyl tail region [65]
PTH1R
Bipartite NLS: RKSWSRWTLALDFKRKARIN
(amino acids 471-478) in carboxyl tail region [71]
FPR2
KIHKK (amino acids 227-231) in the third
cytoplasmic loop [74]
Table 2: Nuclear localization signals of GPCRs
Angiotensin II Receptor 1
Incubation of neuronal cultures with Angiotensin II (Ang II)
induces a time- and dose-dependent increase in the levels of
Angiotensin II Receptor 1 (AT1R) immunoreactivity in the nucleus,
which is prevented by losartan, an AT1 receptor-specific antagonist
[48]. Ang II-induced nuclear localization is specific for AT1 receptor,
because Ang II fails to produce a similar effect on neuronal AT2R. A
putative NLS sequence (KKFKR) is present in the eighth helix of the
cytoplasmic tail of the AT1 but not of AT2R receptor (Table 2) [20,48].
Ang II induces a time- and dose-dependent stimulation of p62
phosphorylation, a glycoprotein of the nuclear pore complex, which is
completely prevented by losartan and not by AT2 receptor specific
antagonists [48]. However, isolated cardiomyocytes indicate the
presence of both AT1R and AT2R proteins that copurify with the
nuclear membrane marker nucleoporin-62 and histone-3, but not
markers of plasma (calpactin-I), Golgi (GRP-78), or endoplasmic
reticulum (GM130) membranes [49]. In isolated nuclei from
cardiomyocytes AT1R and AT2R ligands enhance de novo RNA
synthesis and NFκB mRNA expression, a response that is prevented by
co-administration of AT1R and/or AT2R antagonists. AT1R, but not
AT2R, stimulation increases of Ca2+ concentration in isolated
cardiomyocyte nuclei, and IP3 receptor blockade prevents AT1R-
mediated Ca2+ release and attenuates AT1R-mediated transcription
initiation responses (Table 1) [49].
Apelin Receptor
Nuclear localization of apelin receptor has been demonstrated in
brain and cerebellum-derived D283 Med cells, as well as in human
cerebellum and hypothalamus [20]. The predominant nuclear
localization of the apelin receptor is particularly evident in the
molecular and granular layers of the cerebellum, as well as in the
Citation: Cattaneo F, Parisi M, Fioretti T, Esposito G, Ammendola R (2016) Intranuclear Signaling Cascades Triggered by Nuclear GPCRs. J Cell
Signal 1: 128. 
Page 4 of 9
J Cell Signal, an open access journal Volume 1 • Issue 4 • 1000128
Paraventricular nucleus of the hypothalamus. In the cerebellum there
are three different subcellular distributions for this receptor. The
majority of neurons show expression of the apelin receptor exclusively
in the nucleus, whereas in Purkinje cells it is expressed in both the
nucleus and cytoplasm. In the Paraventricular nucleus of the
hypothalamus, two different subcellular distribution patterns are
observed: smaller parvocellular neurons show apelin receptor
expression in the nucleus, whereas in magnocellular neurons apelin
receptor is expressed in nuclei and cytoplasm [20]. A putative NLS
motif (RKRRR) has been identified in the apelin receptor at the
carboxyl-terminal region of the third intracellular loop (Table 2) [20].
Mutation of Lys242 with Gln prevents nuclear localization of the apelin
receptor, suggesting that RKRRR is a functional NLS motif and that
Lys residue is critical for the nuclear localization [20].
Coagulation Factor II Receptor-like 1
Coagulation Factor II Receptor-like 1 (F2rl1, previously known as
Par2) is expressed to high levels in retinal ganglion cells and is
associated with new blood vessel formation during retinal
development, as well as in ischemic retinopathy. In stimulated retinal
ganglion cells, F2rl1 translocates from the plasma membrane to the cell
nucleus, using a microtubule-dependent shuttle that requires sorting
nexin 11, which contains a NLS motif [50]. Plasma membrane
activation of F2rl1 induces the expression of several genes, including
Ang1, that are involved in vessel maturation. In contrast, nuclear F2rl1
facilitates recruitment of the transcription factor Sp1 to trigger Vegfa
expression and, in turn, neovascularization (Table 1). Mutant
constructs of F2rl1 that inhibit nuclear localization, but not plasma
membrane activation, interfere with Vegfa expression [50].
Platelet-activating Factor Receptor
In nuclei isolated from rat liver, Platelet-activating factor (PAF)
exerts its action through specific nuclear PAF binding sites [51]. PAF
receptor also localizes at the cell nucleus of cerebral microvascular
endothelial cells of newborn pig and cells overexpressing the receptor.
Stimulation of isolated nuclei from porcine cerebral microvascular
endothelial cells (pCMVECs) induces the production of PAF-
molecular species in response to H2O2 and triggers several biological
functions, including transcriptional regulation of cyclooxygenase-2
and inducible nitric oxide synthase (iNOS) [52,53]. In PCECs, brain
endothelial cells and Chinese hamster ovary cells stably overexpressing
PAF stimulation of nuclei with methylcarbamate-PAF triggers a
decrease in cAMP production and a pertussis toxin-sensitive rise in
nuclear calcium [53]. The expression of proinflammatory genes iNOS
and cyclooxygenase-2 is associated with augmented ERKs
phosphorylation and NFκB binding to the DNA consensus sequence
(Table 1) [53].
Moreover, nuclear PAF receptor is responsible for the upregulation
of unique set of growth factors, including vascular endothelial growth
factor, in vitro and ex vivo [54]. Three potential internalization motifs
in the C terminus of the PAF receptor, including a classical NLS, have
been identified in primary human retinal microvascular endothelial
cells. The results show that 311-330 amino-acids residues are essential
for its nuclear localization (Table 2). Furthermore, nuclear localization
of PAF receptor is independent of exogenous PAF stimulation, as well
as intracellular PAF biosynthesis [54].
Lysophosphatidic Acid Receptor
Specific nuclear localization of lysophosphatidic acid receptor-1
(LPA1R) has been demonstrated in pCMVECs, LPA1R stably
transfected HTC4 rat hepatoma cells, and rat liver tissue [55]. LPA1Rs
is dually sequestrated in caveolin-1 and clathrin sub-compartments in
pCMVECs, whereas in nuclear fractions LPA1R is expressed primarily
in caveolae. In pCMVECs and in rat liver nuclei, lysophosphatidic acid
(LPA) stimulation increases [Ca++] as well as the expression of
cyclooxygenase-2 and iNOS, which are prevented by pertussis toxin,
phosphoinositide 3-kinase/Akt inhibitors, Ca++ chelator and channel
blockers (Table 1) [55].
LPA1R traffics from cell membranes to the nucleus in response to
LPA and cell-matrix interaction plays a key role in regulating nuclear
localization of LPA1R [56]. In fact, the RGDS peptide, which blocks
cell matrix-induced integrin clustering and cytoskeletal rearrangement,
reduces the number of cells containing LPA1R in the nucleus. The
same results are obtained by pre-treating cells with Rho kinase or
myosin light chain kinase inhibitors [56]. The addition of LPA to
isolated nuclei expressing LPA1R induces the phosphorylation of
several proteins (Table 1) suggesting that nuclear LPA1R may be
involved in regulating intranuclear protein phosphorylation and
signaling.
Prostaglandin E Receptors
Prostaglandin E receptors (EP) have been detected in nuclear
fractions isolated from porcine brain, myometrium, brain (cortex),
neurons, pCMVECs, HEK 293 cells stably overexpressing EP1 and
endothelial cells [57]. EP3 and the EP4 receptors are also localized on
isolated nuclear membrane fractions of neonatal porcine brain and
adult rat liver [58]. All the nuclear EP receptors are functional. In fact,
their stimulation modulates intranuclear calcium concentration and
the transcription of genes such as iNOS, through a pertussis toxin-
sensitive mechanism (Table 1) [58]. A selective EP3 receptor agonist
also induces increased phosphorylation of ERKs and Akt, which is
prevented by a prostaglandin transporter blocker, actinomycin D,
channel blockers, protein-kinase inhibitors and a NFκB inhibitor, in
nuclei purified from endothelial cells [59,60].
Gonadotropin-Releasing Hormone Receptors
Nuclear localization of Gonadotropin-Releasing Hormone
Receptors (GnRHRs) has been shown initially in C. elegans [61]. The
mammalian type I GnRHR is a structurally unique GPCR that lacks
cytoplasmic tail sequences and displays inefficient plasma membrane
expression. Compared to its murine counterparts, this receptor is
inefficiently folded and retained in the endoplasmic reticulum (ER)
leading to a further reduction on the membrane. In two human cell
lines (HEK 293 and HTR-8/SVneo) GnRHR-1 is expressed in the
cytoplasm and is associated with the ER and nuclear membrane [62].
A molecular analysis of the receptor protein sequence shows a putative
monopartite NLS (KKEKGKK) in the first intracellular loop of GnRH-
RI (Table 2). However, the deletion or the mutation of this sequence
does not alter its spatial distribution on nuclear membranes but is able
to prevent Inositol Phosphate formation in HEK 293 cells.
Gonadotropin-Releasing Hormone treatment of nuclei isolated from
HEK 293 cells stably transfected with GnRH-RI triggers a significant
increase in the acetylation and phosphorylation of histone H3, thereby
revealing that the nuclear-localized receptor is functional (Table 1)
[62].
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Nuclear Opioid Receptors
Nuclear opioid binding sites and nuclear opioid receptors have been
identified in NG108-15 neurohybrid cells and in highly purified nuclei
isolated from hamster ventricular myocardial cells [63,64]. The
exposure of isolated nuclei to dynorphin B, a natural agonist of kappa
opioid receptors, markedly increased opioid peptide gene
transcription. The transcriptional effect is mediated by nuclear PKC
activation and occurs at a higher rate in nuclei from cardiomyopathic
myocytes than in nuclei isolated from normal cells (Table 1) [64].
Leukotriene receptors
In colorectal adenocarcinomas an increased nuclear localization of
the cysteinyl leukotriene 1 (CysLT1) receptor, which binds luekotriene
D4 (LTD4), has been demonstrated [65]. It is mainly expressed in the
outer nuclear membrane in colon cancer cells and in the non-
transformed epithelial cell lines. CysLT1 protein contains a possible
bipartite NLS (310-RKHSLSSVTYVPRKK-324) in its carboxyl tail
region (Table 2). In contrast, no NLS sequence is present in the CysLT2
receptor. Mutagenesis analysis indicates that the predicted NLS
domain is necessary for proper LTD4-induced nuclear translocation of
the CysLT1 receptor [65]. LTD4 stimulation of nuclear CysLT1
receptor induces proliferative ERKs signaling and an increase of [Ca++]
in the nucleus (Table 1). The significance of these experimental
findings is supported by the observed correlation between the
proliferative marker Ki-67 and nuclear CysLT1 receptor localization in
colorectal adenocarcinomas [65].
In human coronary artery smooth muscle cells, lipopolysaccharide
significantly up-regulates the perinuclear expression of CysLT1
receptor and significantly enhances the changes in intracellular
calcium induced by leukotriene C4 (LTC4) [66]. Microarray analysis
reveals, among a number of significantly up-regulated genes after
stimulation with LTC4, a significant increase in mRNA levels for
plasminogen activator inhibitor (PAI)-2 (Table 1) [66]. Oxygen-
glucose deprivation (OGD) induces the translocation of CysLT1
receptor from the cytoplasm to the nucleus in a time-dependent
manner, in EA.hy926 cells. This suggests that in endothelial cells
CysLT1 receptor can translocate to the nucleus in a ligand-
independent manner [67].
PTH/PTHrP receptor
The type 1 PTH/PTH-related peptide receptor (PTH1R) is
associated with the importin family of transport regulatory proteins
[70]. Serum starvation favors nuclear localization of PTH1R, whereas
serum addition or treatment with PTHrP induces its cytoplasmic
localization. In MC3T3-E1 cells chromosomal region maintenance 1
(CRM1) and PTH1R form a complex in vivo and the treatment with
leptomycin B, a specific inhibitor of CRM1-mediated nuclear export,
induces PTH1R accumulation in the nucleus [68-70]. This suggests
that PTH1R shuttles from the nucleus to the cytoplasm under normal
physiological conditions and that this transport is dependent upon
importins and CRM1 [70]. A putative bipartite NLS (471-
RKSWSRWTLALDFKRKARIN-488) in the C-terminus of rat protein
sequence of the PTH1R, has been identified (Table 2). This signal is
functional and plays a role in targeting the PTH1R the nucleus [71].
Glutamate receptors
Metabotropic glutamate receptor, mGlu5, is localized to nuclear
membranes in heterologous cells as well as midbrain and cortical
neurons [72]. Nuclei isolated from mGlu5-expressing HEK cells and
neuronal nuclei respond to the addition of glutamate with rapid,
oscillatory [Ca2+] elevations which are prevented by mGlut5
antagonists or calcium chelators (Table 1) [72].
Extracellular ligands such as glutamate and quisqualate reach
nuclear receptors via both sodium-dependent transporters and cystine
glutamate exchangers. Inhibition of either transport systems blocks
agonist uptake, as well as agonist-induced nuclear Ca2+ changes [73].
In isolated striatal nuclei, nuclear receptor activation results in the de
novo appearance of phosphorylated CREB protein. Thus, activation of
nuclear mGlu5 receptors initiates a signaling cascade that alters gene
transcription and regulates many paradigms of synaptic plasticity [73].
Formyl-peptide Receptors
The Formyl-peptide Receptor (FPR2), which is coupled to pertussis
toxin-sensitive Gi proteins, is the last member of the GPCR family that
has been localized on the nuclear membranes. In fact, FPR2, but not
FPR1 and FPR3, is expressed in nuclei isolated from human lung
carcinoma CaLu-6 and human gastric adenocarcinoma AGS cell lines,
as demonstrated by western blot analysis, immunofluorescence
experiments and radioligand binding assays [74]. Furthermore, in AGS
cells stably transfected with a short hairpin RNA targeting FPR2 (AGS
shFPR2), nuclear FPR2 expression is significantly reduced [74]. FPR2
sequence has been analyzed for the search of NLS by using cNLS
mapper program (http://nls-mapper.iab.keio.ac.jp) [75] and the results
show a stretch of basic aminoacids (227-KIHKK-231) in the third
cytoplasmic loop of the receptor (Table 2). Apelin Receptor and
Urotensin II receptor also show the presence of a NLS in the third
cytoplasmic loop [20]. Multiple alignment of the FPR sequences shows
that K231 of FPR2, within the sequence KIHKK, is replaced by the
polar aminacids Q in FPR1 and N in FPR3. K230 of FPR2 is replaced
by another basic aminoacid (R) in FPR3. Additionally, a HomoloGene/
NCBI database search for the NLS within FPR2 reveals that the
KIHKK sequence has been conserved among species. K230 and K231
are replaced by the basic residues RR in mouse and rat [74].
Nuclear FPR2 is a functional receptor and can respond to a specific
agonist (WKYMVm), since it participates in intra-nuclear Signaling, as
assessed by decreased Gi protein-FPR2 association upon stimulation of
intact nuclei from CaLu-6 and AGS cells with WKYMVm [74].
Effectors associated with post G protein GPCR signaling, including
mitogen-activated protein kinase (MAPK) pathway, are also present in
the nucleus and p42MAPK and p44MAPK are nuclear and
cytoplasmic protein kinases. In both compartments MAPK signal
transduction system is regulated by serine/threonine phosphorylation.
In isolated intact CaLu-6 and AGS nuclei stimulated with WKYMVm,
a time-dependent phosphorylation of nuclear p42MAPK, but not of
p44MAPK, is observed, which is prevented by preincubation with a
FPR2 antagonist (Table 1) [74].
Activated MAPK phosphorylate and activate several transcription
factors, such as c-Jun and c-Myc. In nuclei purified from CaLu-6 and
AGS cells stimulated with WKYMVm, a time-dependent
phosphorylation of the two transcriptional factors in both type of cells
is observed (Table 1) [74]. The nuclear signaling triggered by FPR2 is
not prevented by pertussis toxin, presumably because of its affinity for
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nuclear receptors, lipophilic properties or specific structures assumed
by nuclear receptors [74].
Single (K230A) and multiple (H229A/K230A/K231A) mutagenesis
of the 227-KIHKK-231 show that nuclear localization or translocation
of FPR2 depends on the integrity of the H229 and K231 residues
within the NLS. Accordingly, nuclear expression of FPR1 and FPR3,
where K231 is replaced by the polar aminoacids Q and N, respectively,
has not been observed [74].
Conclusions
GPCRs may be inserted into nuclear membranes for prolonged
periods, compose distinctive signaling units there, and respond to
specific intracellular ligand by transducing nuclear transcriptional
signals that differ from those sent by their plasma membrane
complexes [13]. Several mechanisms according to which GPCRs can
significantly influence nuclear events, have been proposed: i)
activation of the membrane GPCR complex triggers second
messengers which enter in the nucleus and induce processes of cellular
modification; ii) nuclear translocation of protein fragments of GPCRs
that are able to induce ligand-independent signals, or intact GPCRs
that active transcription factors which directly induce or regulate
transcriptional events; iii) constitutive nuclear GPCRs expression.
Molecular mechanism(s) responsible of nuclear localization of GPCRs
include nuclear import of cleaved receptor fragments and chaperone
proteins which facilitate the removal of the receptor from a membrane-
embedded state. Currently, the most plausible explanation for GPCRs
in the nucleoplasm is through transport within micelles, which would
retain a membrane-embedded GPCR suitable for further Signaling in
cells nuclei [76]. The most studied are the molecular mechanism(s)
through which intact GPCRs localize in nuclear membranes of
activated cells, bind their respective cognate agonists in the nuclear
domain, and transduce nuclear transcriptional signals different from
those sent to the nucleus by the same GPCRs in the plasma membrane.
For instance, T cell proliferation by S1P has been linked to signals from
type 1 GPCR for S1P (S1P1) in the plasma membrane, whereas nuclear
S1P1 transduces intracellular S1P suppression of proliferation [77].
The potential biological importance of the difference between nuclear
GPCRs signal transcriptional events and the corresponding plasma
membrane may be considered on different levels: i) GPCRs operate
differently in pre- and post-cell activation stages, both in terms of their
mechanisms of signal transduction and of functional consequences; ii)
prior to cell activation by a GPCR ligand, plasma membrane GPCRs
send one type of nuclear signal, whereas after cell activation and GPCR
nuclearization the subsequent nuclear signals may have different or
even opposite cellular effects [78]. Most of the downstream molecules
normally associated with GPCR signalling at the plasma membrane
have also been found in the nucleus. These include α subunit and βγ
complexes of G-proteins, a number of effector molecules (cAMP,
PLA2, PLCβ1, PLCδ1) and a variety of ion channels [14-18]. Moreover,
the second messengers associated with downstream signalling events
and many of the systems involved in regulation of GPCR signalling
(RGS proteins, β-arrestin-1, GRKs) are also found in the nucleus. This
indicates that nuclear GPCR signalling is tightly regulated, in a manner
analogous to their cell surface counterparts, and hence reinforces the
idea that these receptors are functionally relevant. Nuclear GPCRs can
be constitutively activated or activated by specific ligands, which are
synthesized within the target cell or are internalized from the
extracellular space (intacrine ligands). The potential actions of
intracellular ligands include: i) binding to intracellular membrane
receptors and generation of second messengers; ii) binding to nuclei
and nucleolus; iii) binding to chromatin; iv) binding to receptors on
the endoplasmic reticulum; v) binding to intravescicular receptors with
consequent generation of second messengers [78]. The diverse
functions exerted by many of these ligands suggest that intracrine
signalling may play important roles distinct from those of the same
receptors activated at the cell surface. The discovery of nuclear
receptors open new avenues in the biology of GPCRs, notably in the
molecular mechanisms involved in the control of gene transcription.
Several GPCR agonists do not trigger nucleoplasmic second
messengers and gene expression when acting on nuclear GPCRs,
which play major roles in the effects of prolonged exposure to a specific
ligand. On the other hand, plasma membrane GPCRs play a more
definite role in acute response to stimuli [78]. However, the profile of
genes expressed in response to activation of plasma membrane GPCRs
may differ from that induced by activation of nuclear counterpart.
Further investigations are needed for a clear knowledge of the
biological role of nuclear GPCRs in both physiological and
pathological conditions since final results from these studies may have
a major impact on new therapeutic drug development.
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